Biotech Values

[DewDiligence]

BAX is certainly big enough to carry out its duties in the MNTA collaboration; the question is whether BAX is good enough to do it, and this post from 2010 shows why I have some doubts (#msg-52567644):

BAX appears to be jinxed. They were the main target of the contaminated Chinese heparin in 2008, they botched the manufacturing of Gammagard IVIG and HALO’s Hylenex, and they recently had to write off $600M for an FDA recall of defective infusion pumps that BAX had still not fixed four years after the problem was discovered.

Maybe none of the above is indicative of the success in FoB’s that BAX will ultimately have with MNTA, but I think it’s naïve to assume that BAX will be a great partner just because Craig Wheeler says so.